Page 1 | Search Results | Blood | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

The Role of Alpha 2 Macroglobulin in Chronic Activation of the Complement System in Patients with Chronic Lymphocytic Leukemia

Naseba Naseraldeen, M.A., Regina Michelis, D.Sc, Masad Barhoum, MD, Judith Chezar, PhD, Tamar Tadmor, MD, Ariel Aviv, MD, Lev Shvidel, MD, Adi Litmanovich, Mona Yuklea, MD, Mona Shehadeh, PhD, Ety Shaoul, PhD, Andrei Braester, MD

Blood (2020) 136 (Supplement 1): 17.

https://doi.org/10.1182/blood-2020-141198

Published: 2020

Journal Articles

A Novel Risk-Model to Predict Time to First Treatment (TTT) in Chronic Lymphocytic Leukemia Based on Heavy+Light Chain Immunoparesis and Serum Free Light Chain Analysis: Results from the Israeli CLL Study Group

Tamar Tadmor, MD, Andrei Braester, MD, Najib Dally, MD, Ariel Aviv, Yair Herishanu, MD, Mona Yuklea, MD, Lev Shvidel, MD, Naomi Rahimi-Levene, MD, Rosa Ruchlemer, MD, Ariela Arad, MD, Claudia Fogl, MD, Aaron Polliack, MD, Lee Magal, PhD, Kelly Townsend, PhD

Blood (2018) 132 (Supplement 1): 1849.

https://doi.org/10.1182/blood-2018-99-113771

Published: 2018

Journal Articles

Results of a Phase II of Low-Dose Fludarabine and Cyclophosphamide Combined with Standard Dose Rituximab (FCR-LITE) in Elderly, Untreated Patients with Chronic Lymphocytic Leukemia (CLL): The Israeli CLL Study Group Experience

Tamar Tadmor, MD, Yair Herishanu, MD, Andrei Braester, MD, Osnat Bairey, MD, Ariel Aviv, Naomi Rahimi-Levene, MD, Riva Fineman, MD, Itai Levi, MD, Mona Yuklea, MD, Rosa Ruchlemer, MD, Lev Shvidel, MD, Aaron Polliack, MD

Blood (2018) 132 (Supplement 1): 5566.

https://doi.org/10.1182/blood-2018-99-111681

Published: 2018

Journal Articles

Cancer Registries Often Underestimate the True Incidence of CLL

Rosa Ruchlemer, MD, Miri Zatlawi, Yehudit Fishler, Rita Dichtiar, Barbara Silverman, MD MPH, Ariel Aviv, MD, Ariella Arad, MD, Osnat Bairey, MD, Ohad Binyamini, MD, Andre Braester, MD, Riva Fineman, MD, Neta Goldshmidt, MD, Yair Herishanu, MD, Naomi Rahimi-Levene, Lev Shvidel, MD, Tamar Tadmor, MD, Mona Yuklea, MD, Aaron Polliack, MD, Lital Keinan-Boker, MD PhD MPH

Blood (2014) 124 (21): 5646.

https://doi.org/10.1182/blood.V124.21.5646.5646

Published: 2014

Journal Articles

Richter’s Syndrome In Chronic Lymphocytic Leukemia: Clinical and Laboratory Features In 119 Patients, Attempting To Identify Possible Risk Factors

Tamar Tadmor, MD, Riva Fineman, MD, Lev Shvidel, Osnat Bairey, MD, Neta Goldschmidt, MD, Rosa Ruchlemer, Naomi Rahimi Rachimi, MD, Yair Herishanu, MD, Mona Yuklea, MD,, Ariela Arad, MD, Ariel Aviv, MD, Aaron Polliack, MD

Blood (2013) 122 (21): 5281.

https://doi.org/10.1182/blood.V122.21.5281.5281

Published: 2013

NARROW

The Role of Alpha 2 Macroglobulin in Chronic Activation of the Complement System in Patients with Chronic Lymphocytic Leukemia

A Novel Risk-Model to Predict Time to First Treatment (TTT) in Chronic Lymphocytic Leukemia Based on Heavy+Light Chain Immunoparesis and Serum Free Light Chain Analysis: Results from the Israeli CLL Study Group

Results of a Phase II of Low-Dose Fludarabine and Cyclophosphamide Combined with Standard Dose Rituximab (FCR-LITE) in Elderly, Untreated Patients with Chronic Lymphocytic Leukemia (CLL): The Israeli CLL Study Group Experience

Cancer Registries Often Underestimate the True Incidence of CLL

Richter’s Syndrome In Chronic Lymphocytic Leukemia: Clinical and Laboratory Features In 119 Patients, Attempting To Identify Possible Risk Factors

Email alerts

ASH Publications

American Society of Hematology

The Role of Alpha 2 Macroglobulin in Chronic Activation of the Complement System in Patients with Chronic Lymphocytic Leukemia

A Novel Risk-Model to Predict Time to First Treatment (TTT) in Chronic Lymphocytic Leukemia Based on Heavy+Light Chain Immunoparesis and Serum Free Light Chain Analysis: Results from the Israeli CLL Study Group

Results of a Phase II of Low-Dose Fludarabine and Cyclophosphamide Combined with Standard Dose Rituximab (FCR-LITE) in Elderly, Untreated Patients with Chronic Lymphocytic Leukemia (CLL): The Israeli CLL Study Group Experience

Cancer Registries Often Underestimate the True Incidence of CLL

Richter’s Syndrome In Chronic Lymphocytic Leukemia: Clinical and Laboratory Features In 119 Patients, Attempting To Identify Possible Risk Factors

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only